The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

Findings from two studies highlight the potential for CagriSema, a dual agonist that targets both glucose regulation and appetite control, to improve weight loss in patients with and without type 2 ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.

Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target ...

The Financial Times, reported but not verified by Reuters, covers British Airways and Singapore Airlines canceling flights to ...

Novo Nordisk has presented full Phase 3 trial results for CagriSema, an experimental weight-loss drug, revealing primarily ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...